A survey of combination antidepressant use in Australia

被引:18
作者
Horgan, David
Dodd, Seetal [1 ,2 ]
Berk, Michael [2 ,3 ]
机构
[1] Univ Melbourne, Dept Clin & Biomed Sci, Geelong, Vic, Australia
[2] Univ Melbourne, Barwon Hlth, Geelong, Vic, Australia
[3] Univ Melbourne, Geelong Clin, Geelong, Vic, Australia
关键词
Australia; combination antidepressants; survey; treatment;
D O I
10.1080/10398560601109855
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The aim of this study was to survey doctors working in psychiatry, in Australia about the practice of using two antidepressants simultaneously. Method: A postal survey was sent to all doctors in psychiatry in Australia enquiring about their prescribing history and their attitudes to combination antidepressants and related issues. Results: Seventy-nine percent of respondents had used combination antidepressants. The most frequently reported combination was a selective serotonin reuptake inhibitor combined with a tricyclic antidepressant. Combinations of mirtazepine with venlafaxine and other antidepressants were the next most frequently used. Seventeen percent of respondents reported having seen a complication from combination antidepressants, 75% believed that Australian GPs should be given information on the use of combination antidepressants, 89% wished for more information on this topic, and 88% believed patients had a right to be informed or this option in their treatment. Use of combination antidepressants was more frequent than exceeding the recommended maximum dose of an individual antidepressant. Conclusion: Combination antidepressants are used far more frequently in Australia than suspected previously. Research into safe and evidence-based practice is strongly indicated.
引用
收藏
页码:26 / 29
页数:4
相关论文
共 11 条
[1]  
Bertolote Jose Manoel, 2004, Crisis, V25, P147, DOI 10.1027/0227-5910.25.4.147
[2]   To combine or not to combine? A literature review of antidepressant combination therapy [J].
Dodd, S ;
Horgan, D ;
Malhi, GS ;
Berk, M .
JOURNAL OF AFFECTIVE DISORDERS, 2005, 89 (1-3) :1-11
[3]   Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study [J].
Fava, M ;
Rush, AJ ;
Trivedi, MH ;
Nierenberg, AA ;
Thase, ME ;
Sackeim, HA ;
Quitkin, FM ;
Wisniewski, S ;
Lavori, PW ;
Rosenbaum, JF ;
Kupfer, DJ .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 2003, 26 (02) :457-+
[4]   Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone [J].
Ferreri, M ;
Lavergne, F ;
Berlin, I ;
Payan, C ;
Puech, AJ .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 103 (01) :66-72
[5]   Australia's mental health: an overview of the general population survey [J].
Henderson, S ;
Andrews, G ;
Hall, W .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2000, 34 (02) :197-205
[6]  
HIRSCHFELD RMA, 1994, AM J MED S6A, V97, P33
[7]   Combining antidepressants for treatment-resistant depression: A review [J].
Lam, RW ;
Wan, DDC ;
Cohen, NL ;
Kennedy, SH .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (08) :685-693
[8]   Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance [J].
Maes, M ;
Libbrecht, I ;
van Hunsel, F ;
Campens, D ;
Meltzer, HY .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) :177-182
[9]   Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study [J].
Nelson, JC ;
Maiure, CM ;
Jatlow, PI ;
Bowers, MB ;
Price, LH .
BIOLOGICAL PSYCHIATRY, 2004, 55 (03) :296-300
[10]  
Stahl SM, 2000, ESSENTIAL PSYCHOPHAR